Moreover, CD16-dependent immunomodulatory activity may contribute to the “vaccinal effect” of therapeutic tumor-targeting mAbs, i.e., the promotion of adaptive anti-tumor immune responses that confer long-term protection (17, 18, 28, 29). Here, FCGR3A is linked to neoplasm.